Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...
Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.
Recordati Rare Diseases Inc. today announced the presentation of new data related to its growing portfolio of treatments for rare hematologic disorders at the 67th American Society of Hematology (ASH) ...
The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG ...
Phototherapy is a common treatment for babies with hemolytic disease of the fetus and newborn (HDFN) and severe jaundice.
Medpage Today on MSN
Novel Biologic for Sjogren's Clears Penultimate Hurdle
The drug, dubbed ianalumab, both depletes B cells and deactivates those remaining, Thomas Grader-Beck, MD, of Johns Hopkins ...
Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.
Debt Management: Agios Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between ...
Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.
Lauren Helwig, 24, had been enjoying a perfect weekend away with her family at the vacation hotspot when she ended up on life ...
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a study titled The Burden of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback